Huntington’s disease is an inherited neurodegenerative disorder that causes problems with movement, behavior, and cognitive ...

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

Its potential in Huntington's disease emerged thanks to an AI drug screening platform operated by SOM, which is used to identify existing drugs that can be repurposed for use in new indications.

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder Findings Presented at the 2025 Psychiatry Update Conference ...

SAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive ...

Over the last 7 days, the United States market has risen by 1.8%, contributing to a 10% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this ...

Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

Huntington’s disease is a hereditary disorder that causes a progressive decline in thinking, memory, and the control of movements. On average, the symptoms begin when a person is in their early 40s, ...